Tumor DNA from tumor in situ fluid was used to track evolution of glioma under first-line treatment
TISF-DNA showed high consistency with tumor tissue, showing the genetic landscape of glioma at different stages after surgery. It can even be used to identify false progression during glioma treatment. Even in the absence of imaging findings, glioma DNA recurrence should arouse clinical concern and induce new research.
Authors
- Kaiyuan Deng (ORCID: https://orcid.org/0000-0003-0934-8698)
- Guanzheng Liu (ORCID: https://orcid.org/0000-0002-3692-0314)
- Yushuai Gao
- Jiubing Zhang (ORCID: https://orcid.org/0009-0000-2549-4068)
- Shuang Wu (ORCID: https://orcid.org/0000-0001-5418-6902)
- Sisi Feng (ORCID: https://orcid.org/0000-0002-4472-1905)
- Xingyao Bu (ORCID: https://orcid.org/0000-0002-1541-2185)
- Ziyue Zhang (ORCID: https://orcid.org/0000-0002-6050-779X)
- Li Tao (ORCID: https://orcid.org/0000-0003-0851-1289)
- Zhaoyue Yan
- Dayang Wang
- Jinliang Yu (ORCID: https://orcid.org/0000-0003-2486-659X)
- Liujian Dong (ORCID: https://orcid.org/0000-0003-2623-3198)
Institutions
- Zhengzhou Children's Hospital (CN)
- Henan Provincial People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.3389/fonc.2025.1581173
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Henan Province